Heart attacks linked with antiretroviral treatment

New research has helped to explain why patients being treated with antiretroviral drugs for HIV experience a greater incidence of heart attacks. The research was presented by doctors and researchers from the School of Medicine and Medical Sciences at University College Dublin, the Mater Misericordiae University Hospital in Dublin and the Royal College of Surgeons in Ireland at the Retroviral Conference in Montreal, Canada, on 11 February.

Antiretroviral medications are used to treat a range of infections such as HIV. The new research was based on a major international study that was published in 2008 which showed that HIV patients being treated with antiretroviral drugs have a higher incidence of heart attacks than patients being treated with different drugs.

Doctors at the Royal College of Surgeons in Ireland built on the 2008 study by creating a test to measure platelet activity in the blood of HIV patients. Platelets are essential for external blood clotting when the skin is cut, but if they over activate or mutate inside blood vessels, they can cause internal blood clots, leading to heart attacks.

Results showed that HIV patients taking antiretroviral drugs are more susceptible to heart attacks because the drugs affect the platelets. Why this happens has not yet been established, but the findings pave the way for further research towards improved antiretroviral treatment for HIV patients.

"These findings will significantly affect the management of patients with HIV and have important implications for the treatment of HIV worldwide," says Dr Paddy Mallon, consultant in infectious diseases at the Mater Misericordiae University Hospital in Dublin and a lecturer in medicine at University College Dublin, who led the group researching drug toxicities in HIV.

"The international research published last year showed the link between antiretroviral treatments and increased risk of heart attacks but not the reason why. We have now demonstrated that the use of certain drugs for HIV has a direct effect on platelets within the blood. The results provide invaluable information to help in the search for safe, long term therapies for HIV infection."

Professor Dermot Kenny from the Royal College of Surgeons in Ireland, whose group developed the new test, said that the results demonstrated the value of translational research. "Because of our close collaboration we have seen how the novel diagnostics developed in our lab can move rapidly into the clinic in Ireland. We plan to extend this research to other HIV centres internationally."

For further information, please visit:

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...